ISRG — Intuitive Surgical, Inc.

Summary of ISRG Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Increased 23% year-over-year to $2.77 billion.
• Recurring Revenue: Grew 23% to $2.4 billion, representing 86% of total revenue.
• Total Procedures: Grew 17%, with da Vinci procedures up 16% (847,000) and Ion procedures up 39% (43,000).
• Non-GAAP Operating Margin: Strong at 39%.
• Non-GAAP Net Income: $901 million, up from $662 million in Q1 2025.
• Non-GAAP Earnings Per Share: $2.50, compared to $1.81 in the prior year.
• GAAP Net Income: $822 million or $2.28 per share, up from $698 million or $1.92 per share in Q1 2025.

2. Strategic Updates and Business Highlights

• Procedure Growth: Strong growth in the U.S. and Europe, with da Vinci procedures growing 14% in the U.S. and 19% internationally, although growth in Asia was mixed.
• Capital Placements: 431 da Vinci systems placed in Q1, including 232 da Vinci 5 systems.
• Single Port (SP) Platform: SP procedures grew 68% year-over-year, with ongoing adoption in the U.S. and Korea.
• Digital Ecosystem: Continued investment in data infrastructure and AI capabilities to enhance surgical outcomes and operational efficiencies.
• Clinical Developments: Positive outcomes from clinical studies using Ion technology for lung cancer diagnosis.

3. Forward Guidance and Outlook

• Da Vinci Procedure Growth: Increased forecast for 2026 to a range of 13.5% to 15.5%.
• Gross Profit Margin: Expected to be between 67.5% and 68.5%, reflecting improved product cost reductions.
• Operating Expenses: Anticipated growth of 11% to 14% for the year.
• Other Income: Forecasted to be between $315 million and $335 million, primarily due to lower average cash balances.

4. Bad News, Challenges, or Points of Concern

• Market Challenges in Asia: Continued difficulties in China due to low tender activity and pricing pressures, with Japan also facing slower growth due to fewer system placements.
• Bariatric Procedures: Decline of approximately 10% in da Vinci bariatric procedures, attributed to the rise of GLP-1 medications.
• Cyber Incident: A cyber incident in Q1 led to unauthorized access to customer and corporate data, although it did not significantly impact financial results.

5. Notable Q&A Insights

• Utilization Growth: Management emphasized the importance of utilization rates in driving future placements but did not provide specific quantifiable targets.
• Competitive Landscape: Discussion on competition highlighted the need for Intuitive to articulate the value of its robotic systems beyond price, especially with the introduction of refurbished systems.
• International Strategy: Emphasis on a localized approach to market engagement, with plans to expand manufacturing capabilities in key markets.
• Innovation-led Revenue Growth: Management noted that innovation is critical to driving revenue growth, with a focus on differentiated products that enhance patient outcomes.

Overall, Intuitive Surgical reported a strong start to 2026, with significant growth in procedures and revenue, while also navigating challenges in specific international markets and competitive pressures. The company remains focused on innovation and expanding its digital capabilities to enhance surgical outcomes.